Back HCV Treatment

EASL 2015: Liver Function and Quality of Life Improve after Treatment with Viekira Pak Regimen

Hepatitis C patients treated with AbbVie's Viekira Pak "3D" regimen saw improvements in liver function biomarkers, reported better quality of life, and had increased survival compared to untreated people, according to studies presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. Other research showed that treatment can be cost-effective at all stages of liver disease.


Read more: